To: Critical COVID-19 and neurological dysfunction - a direct comparative analysis between SARS-CoV-2 and other infectious pathogens - Critical Care Science (CCS)
Crit Care Sci. 2023;35(3):335-336
Teixeira-Vaz et al. deserve applause for staging a prospective analysis of neurological dysfunction ensuing after infection from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) versus other pathogens.() While the authors show that critically ill coronavirus disease 2019 (COVID-19) patients are prone to neurological complications, there is a need to consider additional factors in interpreting their research findings.
The index comparison revealed that the COVID-19 group was under sedoanalgesia for a significantly longer duration than the non-COVID-19 group (p = 0.025, with n = 27 in each group). Despite the days under sedoanalgesia not emerging as a factor associated with neurological complications in the small sample-sized univariate analysis conducted by Teixeira-Vaz et al., it remains difficult to draw any meaningful inferences that fall short of knowledge on the nature of sedation.() The former becomes important when the systematic literature links benzodiazepines with an accentuated risk of delirium and dexmedetomidine with an attenuated risk of delirium in critically ill patients.(,) Fraser et al. also suggested increased mechanical ventilation and length of intensive care unit (ICU) stay with benzodiazepine sedation.() The described parameters, even in the study by Teixeira-Vaz et al., could likely have been affected by variables beyond the nature of the underlying disease (SARS-CoV-2 or other infections) unless some protocolized management approach, such as the ABCDEF bundle, was followed by the research group.(,)
[…]
Search
Search in:
Search
Search in:
Teixeira-Vaz et al. deserve applause for staging a prospective analysis of neurological dysfunction ensuing after infection from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) versus other pathogens.() While the authors show that critically ill coronavirus disease 2019 (COVID-19) patients are prone to neurological complications, there is a need to consider additional factors in interpreting their research findings.
The index comparison revealed that the COVID-19 group was under sedoanalgesia for a significantly longer duration than the non-COVID-19 group (p = 0.025, with n = 27 in each group). Despite the days under sedoanalgesia not emerging as a factor associated with neurological complications in the small sample-sized univariate analysis conducted by Teixeira-Vaz et al., it remains difficult to draw any meaningful inferences that fall short of knowledge on the nature of sedation.() The former becomes important when the systematic literature links benzodiazepines with an accentuated risk of delirium and dexmedetomidine with an attenuated risk of delirium in critically ill patients.(,) Fraser et al. also suggested increased mechanical ventilation and length of intensive care unit (ICU) stay with benzodiazepine sedation.() The described parameters, even in the study by Teixeira-Vaz et al., could likely have been affected by variables beyond the nature of the underlying disease (SARS-CoV-2 or other infections) unless some protocolized management approach, such as the ABCDEF bundle, was followed by the research group.(,)
[...]
Comments